Ophthalmology. 1981 Jul;88(7):583-600.
Additional follow-up confirms previous reports from the Diabetic Retinopathy Study (DRS) that photocoagulation, as used in the study, reduces the risk of severe visual loss by 50% or more. Decreases of visual acuity of one or more lines and constriction of peripheral visual field due to treatment were also observed in some eyes. These harmful effects were more frequent and more severe following the DRS xenon technique. The two-year risk of severe visual loss without treatment outweighs the risk of harmful treatment effects for two groups of eyes: (1) eyes with new vessels and preretinal or vitreous hemorrhage; and (2) eyes with new vessels on or within one disc diameter of the optic disc (NVD) equaling or exceeding 1/4 to 1/3 disc area in extent, (Fig 1), even in the absence of preretinal or vitreous hemorrhage. For eyes with these characteristics, prompt treatment is usually advisable. For eyes with less severe retinopathy, DRS findings do not provide a clear choice between prompt treatment or deferral unless progression to these more severe stages occurs.
进一步的随访证实了糖尿病视网膜病变研究（DRS）先前的报告，即该研究中所采用的光凝疗法可将严重视力丧失的风险降低50%或更多。在一些眼睛中还观察到因治疗导致的视力下降一行或多行以及周边视野缩窄。采用DRS氙气技术后，这些有害影响更为频繁和严重。对于两组眼睛而言，未经治疗的严重视力丧失的两年风险超过了有害治疗效果的风险：（1）有新生血管且伴有视网膜前或玻璃体出血的眼睛；（2）视盘上或距视盘一个视盘直径范围内有新生血管（NVD）且范围等于或超过1/4至1/3视盘面积的眼睛（图1），即使没有视网膜前或玻璃体出血。对于具有这些特征的眼睛，通常建议及时治疗。对于视网膜病变不太严重的眼睛，除非进展到这些更严重的阶段，否则DRS的研究结果并不能在及时治疗或延期治疗之间提供明确的选择。
